To evaluate the relationship between the GPR and inflammation-related signaling pathways, the HCC patients in the validation cohort were divided into low-expression and high-expression subgroups according to the expression levels of key molecules (Figure 8A). The gene discussed is ALDH18A1; the disease is hepatocellular carcinoma.